Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gastrointestinal bleeding sometimes causes life-threatening state. It is important to understand the underlining risk factors for prevention and treatment of this condition. In 1997, 81 patients with massive gastrointestinal bleeding were admitted to the life-saving center in Kyoto First Red Cross Hospital. In these patients, 14 subjects (17%) had been receiving hemodialysis. Eight patients (10%) were taking anti-coagulant or antiplatelet drugs. Eight patients (10%) had hypertension and were given calcium antagonists. Seven subjects (9%) had liver cirrhosis and/or
hepatocellular carcinoma
. Because these patients often fall into life-threating state, we must pay special attention to the prevention and cure for gastrointestinal bleeding. For example, it may be necessary to change to heparin free hemodialysis for patients having active bleeding. In anticoagulated patients, it may be required that sufficient hemostatic therapy without risking thromboembolic sequelae. In addition to careful managements, we have better to consider the eradication therapy for all of these high risk groups with
Helicobacter pylori infection
.
...
PMID:[Risk factors for gastrointestinal bleeding]. 978 Jul 11
Chronic hepatitis may progress to cirrhosis and
hepatocellular carcinoma
(
HCC
).
HCC
represents one of the most common human cancers. Incidence rates for this tumor vary widely on a worldwide, suggesting that environmental factors such as infectious microorganisms, carcinogens, or nutrition play a role in its pathogenesis. Several Helicobacter spp. colonize the liver of animals and induce hepatitis. The aim of this study was to determine whether
Helicobacter infection
was associated with HCV-related liver diseases in humans. Liver tissue samples, including biopsy and surgically excised tissues, were collected from patients positive for hepatitis C viruses (HCV) RNA in the serum. Genomic DNA was extracted from sections of formalin-fixed paraffin-embedded tissues by using the QIAamp Tissue Kit and subjected to polymerase chain reaction (PCR) analysis using two sets of Helicobacter-specific 16S ribosomal RNA primers. To identify positive samples for H. pylori, a set of primers specific for a conserved region in the H. pylori vacA gene were also used. The patients' H. pylori status was determined by ELISA. Forty-one patients (mean age 54.9, range 19-78 years; 24 men) were studied. Thirty patients had chronic viral hepatitis (CH) without (N = 18) or with (N = 12) cirrhosis (CIR), and 11 patients had
HCC
. Anti-H. pylori IgG was detected in 54%. The expected 422- and 210-bp fragments of Helicobacter 16S rRNA were amplified from 27% of liver samples, including 17% of CH-CIR and 55% of
HCC
(P = 0.004). The vacA sequence was amplified in 10 of 41(24%) samples (27% of those with
HCC
). These data confirm the presence of H. pylori DNA sequences in human liver and suggest an association of Helicobacter spp. with HCV-related chronic liver diseases. Further studies are needed to ascertain whether Helicobacter spp. infection plays a role in the development of
HCC
.
...
PMID:Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 1214 29
To test whether Helicobacter species play a role in the enhancement of liver necro-inflammation and fibrosis and in the development of
hepatocellular carcinoma
(
HCC
), we sought DNA sequences of Helicobacter species in liver specimens from patients with viral-related chronic hepatitis,
HCC
or metastatic liver carcinoma. We enrolled 28 consecutive patients with ultrasound evidence of hepatic nodule(s) on their first liver biopsy: 21 had histological evidence of
HCC
(Group I) and 7 of metastatic liver carcinoma (Group II). In the same period we observed 27 consecutive patients with chronic hepatitis on their first liver biopsy (Group III). Helicobacter sequences were sought by PCR using primers for the 16S rDNA of Helicobacter spp, designed to amplify a 400 base-pair fragment, and detected by 2% agarose gel and hybridization with a specific biotinylated probe. We used, as positive controls for the DNA extraction from liver tissue, hepatic biopsy sections in which HBV infection was confirmed by HBcAg positivity and in which we amplified HBV-DNA by specific primers; positive controls for the amplification of Helicobacter spp were obtained from gastric biopsy sections in which
Helicobacter pylori infection
was confirmed by biochemical and histochemical tests. HBV-DNA was found in all five HBcAg positive liver biopsies. Helicobacter spp 16S rDNA was detected in all five biopsy specimens of gastric mucosa and in none of liver specimens from patients in any group. Our data suggest that Helicobacter species were not involved in the pathogenesis of virus-related
HCC
, chronic hepatitis or liver carcinoma metastasis.
...
PMID:Helicobacter spp. and liver diseases. 1498 68
Cancer commonly arises at the sites of chronic inflammation and infection. Although this association has long been recognized, the reason has remained unclear. Within the gastrointestinal tract, there are many examples of inflammatory conditions associated with cancer, and these include reflux disease and Barrettos adenocarcinoma of the esophagus,
Helicobacter infection
and gastric cancer, inflammatory bowel disease and colorectal cancer and viral hepatitis leading to
hepatocellular carcinoma
. There are several mechanisms by which chronic inflammation has been postulated to lead to cancer which includes enhanced proliferation in an endless attempt to heal damage, the presence of a persistent inflammatory environment creating a pro-carcinogenic environment and more recently a role for engraftment of circulating marrow-derived stem cells which may contribute to the stromal components of the tumor as well as the tumor mass itself. Here we review the recent advances in our understanding of the contributions of circulating bone marrow-derived stem cells to the formation of tumors in animal models as well as in human beings.
...
PMID:Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. 1648 34
At the present stage of knowledge, the participation of the Helicobacter bacteria in the pathology of liver and the bile tract in humans has not been univocally documented. However, apparent are the premises so as to go on performing the examinations under discussion since the said participation cannot be excluded. If the more direct evidence of the etiologic role of the Helicobacter in the pathology of liver were available, it would create the chances for the more effective treatment of patients than the case has been so far. Cancer commonly derives from the chronic inflammation and infection and in case of
hepatocellular carcinoma
(
HCC
), may arise either from local liver derived progenitor cells (LPCs) or bone marrow originated stem cells (BMSCs) and future studies should disclose the role of either type of cells and of inflammatory factors such as generated by
Helicobacter infection
in the liver pathophysiology.
...
PMID:Helicobacter pylori in liver diseases. 1703 13
Helicobacter DNA has been reported in
hepatocellular carcinoma
tissues in several studies from varying geographic locations, raising the possibility that
Helicobacter infection
may contribute to the pathogenesis of
hepatocellular carcinoma
. Other known risk factors for
hepatocellular carcinoma
show significant geographic variability, but whether the same holds for Helicobacter is unknown. We studied the prevalence of Helicobacter DNA in a US cohort of
hepatocellular carcinoma
, where the prevalence of
Helicobacter infection
is low in the general population. Liver tissues from 57 individuals were examined. Thirty-five individuals had paired tumor/nontumor samples, including 21 cases of
hepatocellular carcinoma
, for a total of 92 samples studied. Both Helicobacter genus and Helicobacter pylori species-specific polymerase chain reaction was performed. Helicobacter DNA was detected in 5 (9%) of 57 cases, all in nonneoplastic cirrhotic liver tissues from individuals with hepatitis C infection (n = 4) or alcohol liver disease (n = 1). Tissues from 22 hepatocellular carcinomas and 10 cholangiocarcinomas were all negative as were tissues from 8 benign primary hepatic tumors. In conclusion, Helicobacter DNA was detectable in 9% of liver tissues in this cohort but was not found in primary benign or malignant liver tumors. These findings indicate that
Helicobacter infection
is unlikely to be etiologically associated with
hepatocellular carcinoma
in this cohort. If
Helicobacter infection
does contribute to the development of
hepatocellular carcinoma
in general, then significant regional variability must exist.
...
PMID:Low frequency of Helicobacter DNA in benign and malignant liver tissues from Baltimore, United States. 1794 88
Helicobacter pylori infection
is one of the most common chronic bacterial infections in humans. The association of other Helicobacter spp. with extragastric diseases in animals is well established, and a role of these bacteria in human liver disease is becoming clearer. Several case-control studies have reported possible associations of Helicobacter spp. with various liver diseases, including
hepatocellular carcinoma
, which is the fifth most common type of carcinoma among men worldwide, and the eighth most common among women. Thus, it is important to understand molecular mechanisms that may lead to hepatotoxicity or hepatocellular dysfunction in which Helicobacter spp. may play a role in inducing malignant transformation of liver cells.
...
PMID:Hepatocellular carcinoma: prevalence and molecular pathogenesis of Helicobacter spp. 1999 89
Recently, it has been shown that
Helicobacter infections
are associated not only with upper gastrointestinal tract diseases but also with extra-gastrointestinal diseases such as cardiovascular, liver or biliary diseases. The contributions of H. pylori to the development of hepatic encephalopathy and hyperammonemia were reported. Some studies demonstrated the effectiveness of H. pylori eradication therapy in hepatic encephalopathy, but these results have not been supported by other reports. H. pylori eradication therapy for the treatment of hyperammonemia and hepatic encephalopathy has not been recommended. The role of H. pylori infection in cholestatic liver diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) is uncertain. Furthermore, the question of whether H. pylori could play a role in the development of
hepatoma
remains controversial. Our study demonstrated that H. pylori infection was one of the independent risk factors for the development of nonalcoholic fatty liver disease (NAFLD). Further investigation is warranted.
...
PMID:[Helicobacter pylori infection and liver diseases]. 2140 38
Obesity is an increasingly serious health problem in nearly all Western countries. It represents an important risk factor for several gastrointestinal diseases, such as gastroesophageal reflux disease, erosive esophagitis, hiatal hernia, Barrett's esophagus, esophageal adenocarcinoma,
Helicobacter pylori infection
, colorectal polyps and cancer, non-alcoholic fatty liver disease, cirrhosis, and
hepatocellular carcinoma
. Surgery is the most effective treatment to date, resulting in sustainable and significant weight loss, along with the resolution of metabolic comorbidities in up to 80% of cases. Many of these conditions can be clinically relevant and have a significant impact on patients undergoing bariatric surgery. There is evidence that the chosen procedure might be changed if specific pathological upper gastrointestinal findings, such as large hiatal hernia or Barrett's esophagus, are detected preoperatively. The value of a routine endoscopy before bariatric surgery in asymptomatic patients (screening esophagogastroduodenoscopy) remains controversial. The common indications for endoscopy in the postoperative bariatric patient include the evaluation of symptoms, the management of complications, and the evaluation of weight loss failure. It is of critical importance for the endoscopist to be familiar with the postoperative anatomy and to work in close collaboration with bariatric surgery colleagues in order to maximize the outcome and safety of endoscopy in this setting. The purpose of this article is to review the role of the endoscopist in a multidisciplinary obesity center as it pertains to the preoperative and postoperative management of bariatric surgery patients.
...
PMID:Role of endoscopy in the bariatric surgery of patients. 2497 15